These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 16075044)

  • 1. Cardiac and skeletal muscle disorders caused by mutations in the intracellular Ca2+ release channels.
    Priori SG; Napolitano C
    J Clin Invest; 2005 Aug; 115(8):2033-8. PubMed ID: 16075044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in RYR1 in malignant hyperthermia and central core disease.
    Robinson R; Carpenter D; Shaw MA; Halsall J; Hopkins P
    Hum Mutat; 2006 Oct; 27(10):977-89. PubMed ID: 16917943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ryanodine receptor channelopathies.
    Benkusky NA; Farrell EF; Valdivia HH
    Biochem Biophys Res Commun; 2004 Oct; 322(4):1280-5. PubMed ID: 15336975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced threshold for store overload-induced Ca
    Chen W; Koop A; Liu Y; Guo W; Wei J; Wang R; MacLennan DH; Dirksen RT; Chen SRW
    Biochem J; 2017 Aug; 474(16):2749-2761. PubMed ID: 28687594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic alterations in myoplasmic Ca2+ in malignant hyperthermia and central core disease.
    Lyfenko AD; Goonasekera SA; Dirksen RT
    Biochem Biophys Res Commun; 2004 Oct; 322(4):1256-66. PubMed ID: 15336973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
    McCarthy TV; Quane KA; Lynch PJ
    Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotype-Phenotype Correlations of Malignant Hyperthermia and Central Core Disease Mutations in the Central Region of the RYR1 Channel.
    Murayama T; Kurebayashi N; Ogawa H; Yamazawa T; Oyamada H; Suzuki J; Kanemaru K; Oguchi K; Iino M; Sakurai T
    Hum Mutat; 2016 Nov; 37(11):1231-1241. PubMed ID: 27586648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional properties of RYR1 mutations identified in Swedish patients with malignant hyperthermia and central core disease.
    Vukcevic M; Broman M; Islander G; Bodelsson M; Ranklev-Twetman E; Müller CR; Treves S
    Anesth Analg; 2010 Jul; 111(1):185-90. PubMed ID: 20142353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional Characterization of C-terminal Ryanodine Receptor 1 Variants Associated with Central Core Disease or Malignant Hyperthermia.
    Parker R; Schiemann AH; Langton E; Bulger T; Pollock N; Bjorksten A; Gillies R; Hutchinson D; Roxburgh R; Stowell KM
    J Neuromuscul Dis; 2017; 4(2):147-158. PubMed ID: 28527222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracellular Ca2+ dynamics in malignant hyperthermia and central core disease: established concepts, new cellular mechanisms involved.
    Avila G
    Cell Calcium; 2005 Feb; 37(2):121-7. PubMed ID: 15589992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiminicore myopathy, central core disease, malignant hyperthermia susceptibility, and RYR1 mutations: one disease with many faces?
    Mathews KD; Moore SA
    Arch Neurol; 2004 Jan; 61(1):27-9. PubMed ID: 14732615
    [No Abstract]   [Full Text] [Related]  

  • 12. The ryanodine receptor: a pivotal Ca2+ regulatory protein and potential therapeutic drug target.
    Dulhunty AF; Casarotto MG; Beard NA
    Curr Drug Targets; 2011 May; 12(5):709-23. PubMed ID: 21291389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dominant and recessive RYR1 mutations in adults with core lesions and mild muscle symptoms.
    Duarte ST; Oliveira J; Santos R; Pereira P; Barroso C; Conceição I; Evangelista T
    Muscle Nerve; 2011 Jul; 44(1):102-8. PubMed ID: 21674524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study of a family with the skeletal muscle RYR1 mutation (c.7354C>T) associated with central core myopathy and malignant hyperthermia susceptibility.
    Taylor A; Lachlan K; Manners RM; Lotery AJ
    J Clin Neurosci; 2012 Jan; 19(1):65-70. PubMed ID: 22030266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Divergent Activity Profiles of Type 1 Ryanodine Receptor Channels Carrying Malignant Hyperthermia and Central Core Disease Mutations in the Amino-Terminal Region.
    Murayama T; Kurebayashi N; Yamazawa T; Oyamada H; Suzuki J; Kanemaru K; Oguchi K; Iino M; Sakurai T
    PLoS One; 2015; 10(6):e0130606. PubMed ID: 26115329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ryanodine receptor channelopathies.
    Betzenhauser MJ; Marks AR
    Pflugers Arch; 2010 Jul; 460(2):467-80. PubMed ID: 20179962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignant hyperthermia-associated mutations in the S2-S3 cytoplasmic loop of type 1 ryanodine receptor calcium channel impair calcium-dependent inactivation.
    Gomez AC; Holford TW; Yamaguchi N
    Am J Physiol Cell Physiol; 2016 Nov; 311(5):C749-C757. PubMed ID: 27558158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ryanodine receptor 1 mutations, dysregulation of calcium homeostasis and neuromuscular disorders.
    Treves S; Anderson AA; Ducreux S; Divet A; Bleunven C; Grasso C; Paesante S; Zorzato F
    Neuromuscul Disord; 2005 Oct; 15(9-10):577-87. PubMed ID: 16084090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional studies of RYR1 mutations in the skeletal muscle ryanodine receptor using human RYR1 complementary DNA.
    Sato K; Pollock N; Stowell KM
    Anesthesiology; 2010 Jun; 112(6):1350-4. PubMed ID: 20461000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Congenital muscle disorders with cores: the ryanodine receptor calcium channel paradigm.
    Treves S; Jungbluth H; Muntoni F; Zorzato F
    Curr Opin Pharmacol; 2008 Jun; 8(3):319-26. PubMed ID: 18313359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.